Education
About Us
Working with TipRanks
Follow Us
Propanc Biopharma (PPCB)
NASDAQ:PPCB
PPCB Stock Chart & Stats
$0.22
$0.00(0.00%)
At close: 4:00 PM EST
$0.22
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.16 - $11.00
Previous CloseN/A
Volume127.03K
Average Volume (3M)400.33K
Market Cap
$3.06M
Enterprise Value$4.01M
Total Cash (Recent Filing)$561.24K
Total Debt (Recent Filing)$1.68M
Price to Earnings (P/E)―
Beta-1.79
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,859,280
10 Day Avg. Volume553,394
30 Day Avg. Volume400,327
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.18
Price to Sales (P/S)0.00
P/FCF Ratio-40.64
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue134.14
Enterprise Value/Gross Profit30.39K
Enterprise Value/Ebitda-0.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityVery low debt (debt-to-equity ~0.01) gives durable financial flexibility for a development-stage biotech, reducing bankruptcy risk and preserving optionality for R&D financing. This structural cushion supports continued clinical programs while the company seeks non-dilutive or strategic funding.
Experienced Scientific Leadership AddedAdding a veteran translational oncology executive strengthens scientific oversight and increases probability of robust preclinical to clinical transition. Over time better governance and development expertise can raise trial success odds and attract partners or grants.
Initial Revenue With Positive Gross MarginEven minimal revenue combined with a ~21% gross margin indicates the company can generate gross profit on recognized activity, signaling early commercial or collaboration traction. Structurally, demonstrated ability to earn gross margin is a positive step toward scalable operations.
Bears Say
Minimal Revenue And Large LossesThe company remains effectively pre-commercial with negligible sales and deeply negative net margins, meaning long-term value depends on successful clinical outcomes or partnerships rather than business operations. Persistent losses erode resources and increase execution risk over months.
Sustained Cash Burn And Negative Operating Cash FlowConsistent negative OCF and ~-$3.1M free cash flow show the business cannot self-fund R&D or operations. Over the medium term this structural cash burn necessitates external financing, increasing dilution or debt reliance and constraining strategic optionality.
Nasdaq Listing-compliance / Delisting RiskA formal minimum bid price deficiency represents a structural corporate-governance and liquidity risk: potential delisting or reverse split can impair access to public capital, reduce liquidity, hinder partner confidence, and complicate long-term financing for clinical programs.
Propanc Biopharma News
PPCB FAQ
What was Propanc Biopharma’s price range in the past 12 months?
Propanc Biopharma lowest stock price was $0.15 and its highest was $11.00 in the past 12 months.
What is Propanc Biopharma’s market cap?
Propanc Biopharma’s market cap is $3.06M.
When is Propanc Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Propanc Biopharma’s earnings last quarter?
Currently, no data Available
Is Propanc Biopharma overvalued?
According to Wall Street analysts Propanc Biopharma’s price is currently Overvalued.
Does Propanc Biopharma pay dividends?
Propanc Biopharma does not currently pay dividends.
What is Propanc Biopharma’s EPS estimate?
Propanc Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Propanc Biopharma have?
Propanc Biopharma has 15,859,280 shares outstanding.
What happened to Propanc Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Propanc Biopharma?
Currently, no hedge funds are holding shares in PPCB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Propanc Biopharma
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Technical Analysis
Verrica Pharmaceuticals
―
―
―
Barinthus Biotherapeutics
―
Telomir Pharmaceuticals, Inc.
―